Podcasts about dohme

To help us unpack all the research and studies we have Dr. Stengler joining us today.In addition to authoring 30 books on health and several best-sellers such as “The Natural Physician's Healing Therapies,” “Prescription for Natural Cures,” “Prescription for Drug Alternatives,” and “Outside the Box Cancer Therapies,” Dr. Stengler has been published in several peer-reviewed medical journals such as The International Journal of Family & Community Medicine, Endocrinology & Metabolism International Journal, and Journal of Nutritional Health & Food Engineering.Dr. Stengler's, NMD. The newest book is called, The Holistic Guide to Gut Health. A comprehensive yet accessible approach to healing leaky gut and the many uncomfortable symptoms it causes. Dr Stengler is also the founder of The Stengler Center for Integrative Medicine.Talking Points:Palmitoylethanolamide (PEA), is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods. Several human studies have demonstrated that PEA has broad-spectrum pain-relieving properties, anti-inflammatory effects, and nerve protection.PEA was first discovered in 1957 by scientists at Merck Sharp & Dohme, who isolated it from egg yolk, peanut meal, and soy lecithin. They found that PEA had anti-inflammatory properties in guinea pigs.However, PEA's role as a potential therapeutic agent was not widely recognized until 1993, when Rita Levi-Montalcini and her colleagues published research that suggested PEA has anti-inflammatory properties. Levi-Montalcini's group termed PEA an autocoid local injury antagonist (ALIA), and suggested that it acts locally to counteract injuryMultiple studies have demonstrated that PEA improves all sorts of pain. For example, a 2023 analysis of 11 studies found that PEA improved pain of various conditions, including muscle and joints, nerves, gynecological, and digestive. In terms of joint pain, a high-quality study demonstrated that PEA significantly reduced adult joint pain compared to placebo. Moreover, 8 clinical trials demonstrated that PEA was effective for low back pain, sciatica, and carpal tunnel syndrome. Even migraine headache pain was shown in published research to be improved with PEA.Lipid mediators help to balance the immune, nervous, and endocrine systems, affecting pain pathways related to inflammation. But unfortunately, due to changing diets, many of us do not get the nutrition and activity we need to make enough PEA ourselves.Supplemental PEA, by Levagen+ is properly formulated for optimal bioavailability, 75% more bioavailable to cell receptors than dietary forms. Levagen+ liposomal delivery of PEA has been clinically studied and shows benefits in joint pain, nerve pain, migraine, infections, sleep, and cognitive function.Learn more about Emerald Labs PEA+ Levagen Use the code: Forever and get 20% off your order. 

To help us unpack all the research and studies we have Dr. Stengler joining us today.In addition to authoring 30 books on health and several best-sellers such as “The Natural Physician's Healing Therapies,” “Prescription for Natural Cures,” “Prescription for Drug Alternatives,” and “Outside the Box Cancer Therapies,” Dr. Stengler has been published in several peer-reviewed medical journals such as The International Journal of Family & Community Medicine, Endocrinology & Metabolism International Journal, and Journal of Nutritional Health & Food Engineering.The newest book is called, The Holistic Guide to Gut Health. A comprehensive yet accessible approach to healing leaky gut and the many uncomfortable symptoms it causes. Dr Stengler is also the founder of The Stengler Center for Integrative Medicine.Talking Points:Palmitoylethanolamide (PEA), is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods. Several human studies have demonstrated that PEA has broad-spectrum pain-relieving properties, anti-inflammatory effects, and nerve protection.PEA was first discovered in 1957 by scientists at Merck Sharp & Dohme, who isolated it from egg yolk, peanut meal, and soy lecithin. They found that PEA had anti-inflammatory properties in guinea pigs.However, PEA's role as a potential therapeutic agent was not widely recognized until 1993, when Rita Levi-Montalcini and her colleagues published research that suggested PEA has anti-inflammatory properties. Levi-Montalcini's group termed PEA an autocoid local injury antagonist (ALIA), and suggested that it acts locally to counteract injuryMultiple studies have demonstrated that PEA improves all sorts of pain. For example, a 2023 analysis of 11 studies found that PEA improved pain of various conditions, including muscle and joints, nerves, gynecological, and digestive. In terms of joint pain, a high-quality study demonstrated that PEA significantly reduced adult joint pain compared to placebo. Moreover, 8 clinical trials demonstrated that PEA was effective for low back pain, sciatica, and carpal tunnel syndrome. Even migraine headache pain was shown in published research to be improved with PEA.Lipid mediators help to balance the immune, nervous, and endocrine systems, affecting pain pathways related to inflammation. But unfortunately, due to changing diets, many of us do not get the nutrition and activity we need to make enough PEA ourselves.Supplemental PEA, by Levagen+ is properly formulated for optimal bioavailability, 75% more bioavailable to cell receptors than dietary formsLevagen+ liposomal delivery of PEA has been clinically studied and shows benefits in joint pain, nerve pain, migraine, infections, sleep, and cognitive function.Learn more about Emerald Labs PEA+ Levagen Use the code: Forever and get 20% off your order.

Comment les rhumatologues peuvent-ils gérer la prescription d'un vaccin en tenant compte des traitements immunosuppresseurs ? Quel est le délai recommandé pour vacciner un patient ayant récemment contracté une infection, et pourquoi ? Quels sont les conseils pour motiver les patients qui hésitent ou ont des inquiétudes face aux vaccins ? Comment adapter les recommandations vaccinales en fonction des spécificités des patients en rhumatologie ? Le Professeur Jacques Morel, rhumatologue au CHU de Montpellier et responsable du centre de référence des maladies auto-immunes, nous éclaire à ce sujet. Notre invité déclare avoir des liens d'intérêt avec : Bristol Myers Squibb, Celltrion, Lilly, Novartis, Pfizer, Sanofi, Merck Sharp and Dohme, Abbvie, Fresenius Kabi, Mylan, Boehringer Ingelheim, Galapagos, Glaxo Smith Kline, Roche, Union Chimique Belge, Janssen, Medac, Sandoz, Nordic Pharma. L'équipe : Comité scientifique :  Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud Listrat, Dr Nicolas Poursac, Dr Céline Vidal, Dr Margaux Moret. Animation : Marguerite de Rodellec Production : MedShake Studio Soutien institutionnel : Pfizer

Quelles sont les raisons principales pour lesquelles les rhumatologues doivent s'intéresser à la vaccination ? Quels sont les nouveaux vaccins susceptibles d'avoir un impact sur les patients suivis en rhumatologie ? Quelles avancées récentes marquent l'actualité dans le domaine des vaccinations ?  Le Professeur Jacques Morel, rhumatologue au CHU de Montpellier et responsable du centre de référence des maladies auto-immunes, nous éclaire à ce sujet. Notre invité déclare avoir des liens d'intérêt avec : Bristol Myers Squibb, Celltrion, Lilly, Novartis, Pfizer, Sanofi, Merck Sharp and Dohme, Abbvie, Fresenius Kabi, Mylan, Boehringer Ingelheim, Galapagos, Glaxo Smith Kline, Roche, Union Chimique Belge, Janssen, Medac, Sandoz, Nordic Pharma. L'équipe : Comité scientifique :  Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud Listrat, Dr Nicolas Poursac, Dr Céline Vidal, Dr Margaux Moret. Animation : Marguerite de Rodellec Production : MedShake Studio Soutien institutionnel : Pfizer

In the previous episode we heard how some rationally-designed therapies work on almost any cancer with the right molecular signature. Tumour-agnostic medications could be godsend for patients with rare cancers which have classically been overlooked by drug developers, and those with advanced cancers of unknown origin. 15,000 such patients have undergone comprehensive genome profiling of their tumours through the organisation, Omico. In this podcast, Omico's founder explains that while the majority have received recommendations about matched therapies, clinical trials are typically the only way to enable access. Professor David Thomas discusses why Australia's Health Technology Assessment process appears to be so conservative and how the market price of next-generation oncotherapies might be brought down by changes across the local ecosystem. Guest Prof David Thomas FRACP PhD (Director, Centre for Molecular Oncology UNSW; Founder and Chief of Science, Omico)  Professor Thomas or Omico have received grants, consultancies or research support from Roche, Astra Zeneca, Pfizer, Eisai, Illumina, Beigene , Elevation Oncology, RedX Pharmaceuticals, SunPharma , Bayer, George Clinical, Novotech , Merck Sharpe and Dohme, Boehringer Ingelheim, Hummingbird, Microba , BioTessellate , PMV Pharma, Australian Unity and Foundation Medicine. ProductionProduced by Mic Cavazzini DPhil. Music licenced from Epidemic Sound includes  ‘Multicolor' and ‘Pulse Voyage' by Chill Cole. ‘Impulsing', ‘the City of Hope' ‘Over Again', and ‘Going Undercover' by Borrtex provided courtesy of FreeMusicArchive. Image by Guido Mieth licenced through Getty Images.  Editorial feedback kindly provided by RACP physicians Simeon Wong, Stephen Bacchi. Thanks also to Kym Bramich and Arnika Martus on staff with Omico and RACP respectively.  Please visit the Pomegranate Health web page for a transcript and supporting references.Login to MyCPD to record listening and reading as a prefilled learning activity. Subscribe to new episode email alerts or search for ‘Pomegranate Health' in Apple Podcasts, Spotify,Castbox or any podcasting app.

The genomic understanding of cancer has transformed a tissue-based classification model that had been dominant for 150 years or more. The last three decades have seen highly targeted therapies developed at blistering pace, and unprecedented improvements in patient outcomes. To date, these advances have been focused on more common cancers. The financing model for drug development means that rare cancers get overlooked, given the small pool of potential buyers relative to the costs and risks of investment. However, the molecular targets characterised in more common cancers are often found in cancers of a different histotype. As such, precision therapies will sometimes have tissue-agnostic efficacy and offer a lifeline for patients with neglected diseases or cancers of unknown origin. Professor David Thomas has founded an NGO called Omico to enable such patients to undergo profiling for hundreds of potential molecular targets. In this interview he explains the rationale for the most promising pan cancer therapies, and in the next episode we discuss changes to the regulatory and funding model required to sustain this screening program. Guest Prof David Thomas FRACP PhD (Director, Centre for Molecular Oncology UNSW; Founder and Chief of Science, Omico) Professor Thomas or Omico have received grants, consultancies or research support from Roche, Astra Zeneca, Pfizer, Eisai, Illumina, Beigene , Elevation Oncology, RedX Pharmaceuticals, SunPharma , Bayer, George Clinical, Novotech , Merck Sharpe and Dohme, Boehringer Ingelheim, Hummingbird, Microba , BioTessellate , PMV Pharma, Australian Unity and Foundation Medicine. ProductionProduced by Mic Cavazzini DPhil. Music licenced from Epidemic Sound includes ‘the Orchard' by Jakob Ahlbom, ‘Dusty Electronics' and ‘Pulse Voyage' by Chill Cole, ‘Tam' by LJ Kruzer, ‘See you soon' and ‘Going Undercover' by Borrtex. Image by filo licenced through Getty Images. Editorial feedback was kindly provided by RACP physicians Nichola Ball, Stephen Bacchi, Aafreen Khalid, Simeon Wong, Maansi Arora and Aidan Tan.Please visit the Pomegranate Health web page for a transcript and supporting references.Login to MyCPD to record listening and reading as a prefilled learning activity. Subscribe to new episode email alerts or search for ‘Pomegranate Health' in Apple Podcasts, Spotify,Castbox or any podcasting app.

While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on January 3rd, 2025! Have an awesome holiday season!On this podcast, we speak to Artiva Biotherapeutics' CEO, Fred Aslan, M.D.The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August 2023, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease.AlloNK (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the out-patient setting. Artiva is investigating AlloNK in a phase 1/2 multicenter clinical trial to assess the safety and clinical activity of AlloNK alone and in combination with the anti-CD20 monoclonal antibody, rituximab, in patients with relapsed or refractory B-cell-non-Hodgkin lymphoma (B-NHL). Artiva is also investigating the safety and clinical activity of AlloNK in combination with rituximab in patients with lupus nephritis. In addition, Artiva is collaborating with Affimed in a phase 2, open-label, multi-center, multi-cohort study, testing a combination therapy, comprised of AlloNK and the innate cell engager AFM13, for the treatment of patients with relapsed/refractory CD30-positive lymphomas. Artiva selects cord blood units with the high affinity variant of the CD16 receptor and a KIR-B haplotype for enhanced product activity. Using the company's cell therapy manufacturing platform, Artiva can generate thousands of doses of pure, cryopreserved, infusion-ready NK cells from a single umbilical cord blood unit while retaining the high and consistent expression of CD16 and other activating NK receptors, without the need for engineering. AlloNK is being administered in the outpatient setting over multiple doses and multiple cycles.Artiva's pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and for which an IND has been allowed by FDA, and a pipeline of CAR-NK candidates targeting both solid and hematopoietic cancers. Artiva has also entered into therapeutic NK cell collaborations with Merck Sharp & Dohme. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Am 23.09.2024 fiel der Startschuss der „BRCA Awareness Week“, die in Anlehnung an die „National Hereditary Cancer Week“ darauf abzielt, das Bewusstsein für BRCA 1/2- assoziierten Brustkrebs zu schärfen. Wusstet ihr, dass jede*r diese Gene in sich trägt, aber eine Mutation auf diesen Genen zu einem erhöhten Krebsrisiko führt? Protagonistin dieser Folge ist Nicole Kultau: Brustkrebsaktivistin, Bloggerin und selbst Betroffene Frau. Wir erfahren von ihr, wie es war, als sie den positiven Befund bekommen hat, welche Risiken diese Mutation birgt, aber auch, welche Möglichkeiten es gibt. Wir bedanken uns herzlich bei AstraZeneca und MSD Sharp und Dohme für die Unterstützung dieser Folge.

On this special episode offering CPE Credits, Fred Goldstein Invites Susan Wojcicki Roman, clinical pharmacy lead at Humana Pharmacy Solutions to discuss Breaking Biases in Breast Cancer. This activity is supported by an independent medical education grant from Novartis Pharmaceuticals Corporation and Merck Sharp and Dohme. AMCP is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Full instructions on how to claim CPE credits can be found here (https://acrobat.adobe.com/id/urn:aaid:sc:VA6C2:cce0dc42-2b1b-4e42-8543-d1c93730e81d) Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

On this special episode offering CPE Credits, Fred Goldstein Invites Danielle Roman, manager of clinical pharmacy services at Allegheny Health Network Cancer Institute to discuss Breast Cancer Breakthroughs: A Peek into the Pipeline. This activity is supported by an independent medical education grant from Novartis Pharmaceuticals Corporation and Merck Sharp and Dohme. AMCP is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Full instructions on how to claim CPE credits can be found here (https://acrobat.adobe.com/id/urn:aaid:sc:VA6C2:cce0dc42-2b1b-4e42-8543-d1c93730e81d) Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Tercera hora de Visión Global en Radio Intereconomía que empezamos con nuestro consultorio de Wall Street en el que nos acompaña Juan Ignacio Marrón, analista independiente y fundador de @InversoresInstitucionales. Con él analizamos compañías como Carvana, Advanced Micro Devices, Paypal, Bavarian Nordic, AMC Entertainment Holdings, Intuitive Surgical, ASML Holding, Broadcom, SuperMicro, Merck Sharp and Dohme, Mercedes-Benz Group, Hershey Company, General Motors. Después, último vistazo a los mercados y repasamos titulares empresariales con Estefanía Muniz y María de la Cerca. Habalmos del FROB, la sanción a la SGAE, Endesa, Solarpack y Shell. Terminamos con el análisis en el que nos acompaña Samuel Abraldes, CEO de Socaire. Con él, analizamos y hacemos balance de la jornada en los mercados en un día marcado por la indefinición en los índices de Wall Street.

Join Prof. Francesco Giorgino and Dr. Darren McGuire as they discuss personalisation of treatment for patients with both type 2 diabetes and cardiovascular disease. For more free education, go to ⁠⁠⁠⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠⁠⁠⁠⁠@dkipractice⁠⁠⁠⁠⁠⁠) or connect on ⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠. Faculty disclosures Prof. Francesco Giorgino Grants or contracts: Eli Lilly, Roche Diabetes Care Consulting: Eli Lilly, Novo Nordisk Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi Dr. Darren K. McGuire Clinical trial leadership: - Former: Esperion, AstraZeneca, CSL Behring - Current: Novo Nordisk, Lilly USA, Pfizer, Boehringer Ingelheim, NewAmsterdam Consultancy: - Former: Merck & Co - Current: Lilly USA, Boehringer Ingelheim, Novo Nordisk, Bayer, Lexicon, Altimmune, Esperion, Intercept Pharmaceuticals, Applied Therapeutics Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education. Accreditation information Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Join Prof. Francesco Giorgino and Dr. Shehla Shaikh as they discuss strategies to help support type 2 diabetes patients during cultural events, such as observation of Ramadan. For more free education, go to ⁠⁠⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠⁠⁠⁠@dkipractice⁠⁠⁠⁠⁠) or connect on ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠. Prof. Francesco Giorgino Grants or contracts: Eli Lilly, Roche Diabetes Care Consulting: Eli Lilly, Novo Nordisk Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi Dr. Shehla Shaikh Dr. Shaikh declares no current financial conflict of interest Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education. Accreditation information Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Join Prof. Francesco Giorgino and Dr. Alice Cheng for a discussion on the importance of being culturally sensitive during shared decision-making in type 2 diabetes care. For more free education, go to ⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠⁠@dkipractice⁠⁠⁠) or connect on ⁠⁠LinkedIn⁠⁠⁠. Faculty disclosures Prof. Francesco Giorgino Grants or contracts: Eli Lilly, Roche Diabetes Care Consulting: Eli Lilly, Novo Nordisk Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi Dr. Alice Cheng Advisory Board: Abbott, AstraZeneca, Bayer Speakers Bureau: Abbott, Amgen, AstraZeneca, Bausch, Bayer Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education. Accreditation information Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Discussion of Off-Label, Investigational, or Experimental Drug Use: None

This episode of the Inclusive Enterprise Podcast features a conversation with Josette Gbemudu, Executive Director of Health Equity and Social Determinants of Health at Merck.  Merck & Company, Inc, is an American multinational pharmaceutical company, headquartered in Rahway, New Jersey and is recognized as Merck sharp and Dohme or MSD outside of the United States and Canada. It's one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.  Merck & Co. aspires to be the premier research-intensive biopharmaceutical company in the world and today is at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.With 15 years of experience, Josette thrives at the intersection of commercial strategy, innovation, and policy. She has brought this expertise to key sectors including the Pharmaceutical Industry, Federal and State Health Agencies, Health Plans and Providers. She has a strong understanding of the macro and micro healthcare ecosystem and the interdependencies across critical stakeholders.Join the ConversationListen to this episode of The Inclusive Enterprise Podcast: “Taking Health Equity from Concept to Practice: Driving Transformational and Sustainable Change - A Conversation with Josette Gbemudu" as we explore workplace health equity strategy with Josette including:The rationale for hospitals, health systems, and other health providers for making health equity an even greater priority after Covid-19Why all other industries should be seriously concerned and take action to reduce disparities and advance health equityHow healthcare and non-healthcare organizations can positively impact community health and close gaps in care by leveraging new and innovative partnershipsJosette also shares the key pillars for improving health equity long term results. How do you engage everyone to contribute to better outcomes?Listen to an effective approach to motivate every leader and employee across all industries to participate in achieving health equity within communities.REMEMBER - To inspire individual and collective action key enablers are needed: leadership commitment, shared vision and scope linked to business objectives, measurement framework linked to short and long-term impact metrics, and sustained focus.At Inclusive Leaders Group, we help leaders create safe, inclusive spaces that elevate employee engagement and performance to improve the business results and the communities they serve.You can find information about Inclusive Leaders Group's consulting, training, and assessment services at inclusiveleadersgroup.com. And while there, please subscribe to the Inclusive Enterprise Podcast for this and other informative and enlightening episodes.We help leaders create safe, inclusive spaces that elevate employee engagement and performance to improve the business results and the communities they serve.

Join Prof. Francesco Giorgino and Dr. Erika Bezerra Parente as they identify some takeaways from EASD 2023, including data and discussions on treatment non-adherence, SGLT2 inhibitors, and stigma For more free education, go to ⁠diabetes.knowledgeintopractice.com⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠@dkipractice⁠⁠) or connect on ⁠LinkedIn⁠⁠. Faculty disclosures Prof. Francesco Giorgino Grants or contracts: Eli Lilly, Roche Diabetes Care Consulting: Eli Lilly, Novo Nordisk Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi Dr. Erika Bezerra Parente Honoraria for lectures, presentations and education events: Sanofi Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education. Accreditation information Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Discussion of Off-Label, Investigational, or Experimental Drug Use: None

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/JTS865. CME/MOC/AAPA credit will be available until November 13, 2024.Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; and Lilly.Grant/Research Support from AstraZeneca.Speaker for AstraZeneca; Daiichi Sankyo, Inc.; and F. Hoffmann-La Roche Ltd/Genentech, Inc.Faculty/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, lnc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biophanna Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, lnc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer lngelheim Pharmaceuticals, lnc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serano, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; lmmunoGen, Inc.; lmmunomedics, Inc.; lncyte; Infinity Pharmaceuticals, Inc.; lnvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, lnc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; Medlmmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove lnc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr lmmunotherapeutics; Plexxikon; Radius Health, lnc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen lnc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, lnc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; Taplmmune lnc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks (all paid to institution).Faculty/PlannerYelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck and Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck and Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.Stock Shareholder in Inspirna, Inc.Faculty/PlannerAntonio Passaro, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; GSK; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Sharp and Dohme; Mundipharma International; Novartis AG; Pfizer; and Takeda Pharmaceutical Company Limited.Grant/Research Support from ArriVent Biopharma; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Serono; Merck Sharp and Dohme; Mirati Therapeutics, Inc.; Pfizer; and RMC Pharmaceutical Solutions Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/JTS865. CME/MOC/AAPA credit will be available until November 13, 2024.Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; and Lilly.Grant/Research Support from AstraZeneca.Speaker for AstraZeneca; Daiichi Sankyo, Inc.; and F. Hoffmann-La Roche Ltd/Genentech, Inc.Faculty/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, lnc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biophanna Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, lnc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer lngelheim Pharmaceuticals, lnc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serano, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; lmmunoGen, Inc.; lmmunomedics, Inc.; lncyte; Infinity Pharmaceuticals, Inc.; lnvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, lnc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; Medlmmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove lnc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr lmmunotherapeutics; Plexxikon; Radius Health, lnc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen lnc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, lnc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; Taplmmune lnc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks (all paid to institution).Faculty/PlannerYelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck and Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck and Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.Stock Shareholder in Inspirna, Inc.Faculty/PlannerAntonio Passaro, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; GSK; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Sharp and Dohme; Mundipharma International; Novartis AG; Pfizer; and Takeda Pharmaceutical Company Limited.Grant/Research Support from ArriVent Biopharma; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Serono; Merck Sharp and Dohme; Mirati Therapeutics, Inc.; Pfizer; and RMC Pharmaceutical Solutions Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/JTS865. CME/MOC/AAPA credit will be available until November 13, 2024.Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; and Lilly.Grant/Research Support from AstraZeneca.Speaker for AstraZeneca; Daiichi Sankyo, Inc.; and F. Hoffmann-La Roche Ltd/Genentech, Inc.Faculty/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, lnc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biophanna Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, lnc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer lngelheim Pharmaceuticals, lnc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serano, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; lmmunoGen, Inc.; lmmunomedics, Inc.; lncyte; Infinity Pharmaceuticals, Inc.; lnvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, lnc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; Medlmmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove lnc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr lmmunotherapeutics; Plexxikon; Radius Health, lnc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen lnc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, lnc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; Taplmmune lnc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks (all paid to institution).Faculty/PlannerYelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck and Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck and Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.Stock Shareholder in Inspirna, Inc.Faculty/PlannerAntonio Passaro, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; GSK; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Sharp and Dohme; Mundipharma International; Novartis AG; Pfizer; and Takeda Pharmaceutical Company Limited.Grant/Research Support from ArriVent Biopharma; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Serono; Merck Sharp and Dohme; Mirati Therapeutics, Inc.; Pfizer; and RMC Pharmaceutical Solutions Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/JTS865. CME/MOC/AAPA credit will be available until November 13, 2024.Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; and Lilly.Grant/Research Support from AstraZeneca.Speaker for AstraZeneca; Daiichi Sankyo, Inc.; and F. Hoffmann-La Roche Ltd/Genentech, Inc.Faculty/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, lnc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biophanna Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, lnc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer lngelheim Pharmaceuticals, lnc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serano, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; lmmunoGen, Inc.; lmmunomedics, Inc.; lncyte; Infinity Pharmaceuticals, Inc.; lnvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, lnc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; Medlmmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove lnc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr lmmunotherapeutics; Plexxikon; Radius Health, lnc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen lnc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, lnc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; Taplmmune lnc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks (all paid to institution).Faculty/PlannerYelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck and Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck and Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.Stock Shareholder in Inspirna, Inc.Faculty/PlannerAntonio Passaro, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; GSK; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Sharp and Dohme; Mundipharma International; Novartis AG; Pfizer; and Takeda Pharmaceutical Company Limited.Grant/Research Support from ArriVent Biopharma; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Serono; Merck Sharp and Dohme; Mirati Therapeutics, Inc.; Pfizer; and RMC Pharmaceutical Solutions Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This week, we speak to Artiva Biotherapeutics' CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease.AlloNK (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the out-patient setting. Artiva is investigating AlloNK in a phase 1/2 multicenter clinical trial to assess the safety and clinical activity of AlloNK alone and in combination with the anti-CD20 monoclonal antibody, rituximab, in patients with relapsed or refractory B-cell-non-Hodgkin lymphoma (B-NHL). Artiva is also investigating the safety and clinical activity of AlloNK in combination with rituximab in patients with lupus nephritis. In addition, Artiva is collaborating with Affimed in a phase 2, open-label, multi-center, multi-cohort study, testing a combination therapy, comprised of AlloNK and the innate cell engager AFM13, for the treatment of patients with relapsed/refractory CD30-positive lymphomas. Artiva selects cord blood units with the high affinity variant of the CD16 receptor and a KIR-B haplotype for enhanced product activity. Using the company's cell therapy manufacturing platform, Artiva can generate thousands of doses of pure, cryopreserved, infusion-ready NK cells from a single umbilical cord blood unit while retaining the high and consistent expression of CD16 and other activating NK receptors, without the need for engineering. AlloNK is being administered in the outpatient setting over multiple doses and multiple cycles.Artiva's pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and for which an IND has been allowed by FDA, and a pipeline of CAR-NK candidates targeting both solid and hematopoietic cancers. Artiva has also entered into therapeutic NK cell collaborations with Merck Sharp & Dohme. 

In this epsisode Prof. Francisco Giorgino & Dr. Vanita Aroda explore how vital it is that we aim to control more than blood glucose levels when treating type 2 diabetes patients and whether we should strive for a balance by achieving weight, cardiovascular and renal targets as well. For more free education, go to diabetes.knowledgeintopractice.com⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice⁠) or connect on LinkedIn⁠. Disclosures Prof. Francisco Giorgino: Grants or contracts: Eli Lilly, Roche Diabetes Care Consulting: Eli Lilly, Novo Nordisk Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi Dr. Vanita Aroda: Consulting: Applied Therapeutics, Fractyl, Pfizer, Novo Nordisk, Sanofi Research Support: Applied Therapeutics, Eli Lilly, Fractyl, Novo Nordisk, Sanofi Target Audience: Specialty: Primary care physicians (PCPs), endocrinologists, cardiologists, diabetologists Geographic: Global (ex US and UK audiences) Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.

Join Prof. Francisco Giorgino & Dr. Richard E. Pratley as they discuss their highlights from the 83rd American Diabetes Association (ADA 2023) congress. The congress featured over 200 scientific sessions and symposia, and 1,400 posters. Among the topics discussed are trials investigating therapies to treat obesity in patients with type 2 diabetes (T2D), as well as discussion about remission and what it really means for T2D. For more free education, go to ⁠diabetes.knowledgeintopractice.com⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠@dkipractice⁠) or connect on ⁠LinkedIn⁠. Disclosures Prof. Francisco Giorgino: Grants or contracts: Eli Lilly, Roche Diabetes Care Consulting: Eli Lilly, Novo Nordisk Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi Dr. Richard E. Pratley Research grant: Dompe, Novo Nordisk Honoraria for lectures, presentations and education events: Merck, Novo Nordisk Consulting: Bayer AG, Endogenex Inc., Gasherbrum Bio Inc., Henguri (USA) Ltd. Intas Pharmaceuticals Inc. Eli Lilly, Merck, Novo Nordisk, Pfizer, Rivus Pharmaceuticals Inc., Sun Pharmaceutical Industries Target Audience: Specialty: Primary care physicians (PCPs), endocrinologists, cardiologists, diabetologists Geographic: Global (ex US and UK audiences) Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.

Casey Dohme is the founder and owner of The Blind Rhino The Blind Rhino is a popular, award-winning Sports Bar with two brick & mortar locations in Fairfield County, CT! Their flagship location opened October 2015 in historic downtown South Norwalk, CT, and their newest store launched 2019 in the Black Rock section of Bridgeport, CT! Blind Rhino also has a Food Truck that they launched in 2022, as well as TWO food trailers that are posted up full time at Half Full Third Place in Stamford, CT & Tribus Beer Co. in Milford, CT Blind Rhino have won over 25 awards for their wings! Receiving awards in Connecticut, Maine, New York (Buffalo, Westchester, Hudson Valley), Rhode Island & New Jersey! The Blind Rhino has also been awarded the Best Sports Bar in Fairfield County 6 times at Best of the Gold Coast as well has having been recognized every year by Connecticut Magazine in the Best Restaurants issue, for everything from Best Beer Bar, Best Pub, Best Chicken Wings & even Best Nachos! I had such an awesome conversation with Casey, getting to learn about his journey through the food and hospitality industry, how the Blind Rhino came to be, the many wing competitions the Rhino has won, the building and development of the bar, what makes them stand out from other sports bars in the area, the charity tournaments they host, what the Rhino is up to today and so much more!  Episode Sponsors: Uncle Matts Bakery and Cafe - ⁠⁠https://unclemattsbakeryandcafe.com/⁠⁠ BD Provisions - ⁠⁠https://www.bdprovisions.com/⁠⁠ Around Town Real Estate - ⁠⁠https://www.aroundtownrealestatect.com/

Hosts Gil Bashe and Gregg Masters welcome Dr. Junaid Bajwa, Chief Medical Scientist at Microsoft Research and a practicing physician in the NHS (the UK's National Health Service). Dr. Bajwa was previously the Global Lead for Strategic Alliances and Solutions for the Global Digital Centre of Excellence at Merck Sharp & Dohme. He cofounded “VelocityHealth”, Europe's first prevention focused digital-health accelerator, in partnership with Telefonica, and led his team to deliver the “NHS Testbed” in partnership with Verily Life Sciences (part of Alphabet), which the Health Service Journal recognized as the “Best Pharmaceutical Partnership with the NHS” in 2018. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio.” Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

James Gallagher asks whether a weight-loss drug on the NHS heralds a new era in tackling obesity? He meets Jan who lost nearly 4 stone after being part of a trial taking a weekly injection of Semaglutide for 15 months alongside advice on meals and exercise. However, when people stop taking the drug the weight starts to go back on. Add to that supply shortages with heightened private demand and some doctors think the drug is as controversial as they come. James unpicks the ethical and societal dilemmas against a backdrop of half the world's population projected to be overweight or obese by 2035. Producer: Erika Wright Declared interests Dr Margaret McCartney: "No conflicts to declare." Prof Sir Stephen O'Rahilly : "in the past has been a remunerated consultant and has had research collaboration with Novo Nordisk." Professor Naveed Sattar: "consulted for and/or received speaker honoraria from Novo Nordisk, Abbott Laboratories, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Pfizer, and Sanofi; and grant support paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics. He was a co-investigator in lifestyle trials such as DiRECT and co-lead for STANDby."

This week is the story of Melissa Dohme who was brutally attacked by her ex-boyfriend. There is a happy ending though. Listen as this week has a lot of twists and turns! Merchandise: https://did-not-need-to-know.creator-spring.com/Instagram: https://www.instagram.com/didnotneedtoknow/Facebook: https://www.facebook.com/DNNTKpodcastTwitter: https://twitter.com/dnntkpodcastWebsite: https://https://www.didnotneedtoknow.com

No episódio de hoje, a atriz Karina Dohme conta a história de um jantar de aniversário de namoro, que tinha tudo pra ser super picante, mas acabou provocando uma indigestão amorosa. Ficou curioso? Então dá o play em mais episódio do “Posso mandar áudio?”, que acabou de sair do forno.

This week Mariah is joined by a very special guest - Leslie! Join us as Mariah tells us about the amazing survival story of Melissa Dohme. *If you, or someone you know, is in an abusive relationship you can call the National Domestic Abuse hotline at 800 – 799 – 7233 or text “START” to 88788.* Connect with us: Insta: @whoresforhorror Twitter: @whrs4horror Gmail: whores4horror69@gmail.com Send a voice message: https://anchor.fm/mariah-kay/message Sources: https://www.thehotline.org/ https://closeronline.co.uk/real-life/news/melissa-dohme-stabbed-32-times-ex-now-engaged-paramedic-saved-life/ https://www.bbc.com/news/magazine-38302839 https://www.wtkr.com/news/only-on-3-she-was-stabbed-32-times-after-being-brutally-attacked-by-her-ex-boyfriend-a-domestic-violence-survivor-shares-her-story https://www.cbsnews.com/news/melissa-dohmes-survival-story-48-hours-live-to-tell-one-last-hug/ https://www.fox13news.com/news/domestic-violence-survivor-inspires-others-with-her-story https://www.christianpost.com/news/god-saved-me-woman-forgives-ex-boyfriend-who-stabbed-her-32-times.html --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/mariah-kay/message

The past year has included the release of new guidelines on cardiovascular disease prevention and further data on cardioprotective agents in type 2 diabetes. In this episode we speak to Prof. Naveed Sattar about these guidelines and how best to help people with type 2 diabetes to reduce their cardiovascular risk. By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References available here Disclosures: Prof. Naveed Sattar declares the following financial relationships from the past 24 months: Advisory - Afimmune, Amgen, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi Consulting - Abbott Laboratories, Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi Speaker honoraria - Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi Grant funding - AstraZeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Efpeglenatide for type 2 diabetes Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Antenados #129 - Danilo Gobatto conversa com Lilia Cabral e Giulia Bertolli, que estão em cartaz no Teatro Vivo, em São Paulo, com o espetáculo “A Lista”. Tem também um bate papo com a atriz e empresária Karina Dohme sobre as novidades da carreira! Apresentação: Danilo Gobatto e Sonorização: Cayami Martins.

Even if you are stabbed in the face and neck almost 20 times or set on fire, burning 80% of your body, you can survive! These 2 ladies did. Sources: https://www.cbsnews.com/pictures/meliss-dohmes-brutal-attack-and-incredible-recovery-22/ https://www.cbsnews.com/news/48-hours-stabbed-32-times-dating-violence-survivor-speaks/ Music/SFX: https://www.epidemicsound.com/  Support the show

Crime Family, we're glad you're here, and WOW are you in for a wild ride this week. Beth brings you installment 5 of Architect Mayhem with an Architect who loses everything: partly due to circumstance and largely his own actions, then vents his fury on someone who just tried to help him. Bailey has a rough story of a woman who goes through hell with a partner but finds the best kind of happiness in her survival and fortitude. This one is worth the rollercoaster you have to go through to reach the finale. And this week we are sharing with you the trailer for Mums, Mysteries, and Murder, a pair of friends, Marti and Effie, who live in Australia and Scotland, who take turns sharing True Crime stories. They are warm and funny and have great rapport, so we really think you'll love them! Thank you for being here for Episode 19, everyone. Have a seat. You might need something hard in your glass for this one.

This week we are joined by Dr. Lea-Cathrin Dohme from Cardiff Metropolitan University. With Dr. Dohme we discuss the development of Psychological Skills and Characteristics in young athletes. The conversation touches on the distinction between skills and characteristics, identifying athlete needs, roles and expectations for coaches, and the impact we can have as coaches. The Coach's Road Podcast is proud to be presented by CoachTools, a tool to improve coaching and power your club's philosophy! If you are interested in using CoachTools go to www.coachtools.net and fill out the “Start Free Trial” Form and mention we sent you! Don't forget to check out the rest of the resources from our guests on our drive: https://bit.ly/t-c-r-drive. You can also catch all of the presentations from the first ever Coach's Road Conference on our YouTube channel! Thanks for Listening!

 20/01/2022. Адміністрація терапевтичних товарів (TGA) надає дозвіл на вакцину Novavax та попередньо схвалює два пероральних противірусних методи лікування COVID-19. Нові ліки Merck Sharp and Dohme's, Paxlovid,  Pfizer's Lagevrio  прибудуть до Австралії незадовго, але вони не замінятимуть вакцинування. Тенісний турнір у Мельбурні та ковідні перипетії. Про це та більше на хвиялх SBS Ukrainian...

Today we're joined by Professor Naveed Sattar for a summary of some of the key takeaways from the International Diabetes Federation Virtual Congress 2021. Professor Sattar is Professor of Metabolic Medicine at the University of Glasgow, and was Committee Lead for the Cardiovascular Disease & Hypertension stream at the congress. For more free education, go to diabetes.knowledgeintopractice.com, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice) or connect on LinkedIn. Disclosures: Professor Naveed Sattar declares the following: Advisory board: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi Speaker honoraria: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi Institutional research grant: Boehringer Ingelheim All conflicts have been mitigated prior to this activity. This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Mr. Temitayo (Tayo) Erogbogbo, is Global Advocacy Director of MSD for Mothers (https://www.msdformothers.com/), at Merck Sharp & Dohme. Tayo has two decades of combined private sector and international development experience, 13 years of which was spent in the pharmaceutical industry in multiple roles across community relations, government affairs, marketing and sales. As the Global Advocacy Director of MSD for Mothers, Tayo is responsible for global and national strategic partnerships and programs to bring about policies and practice changes to improve maternal health care, and strengthen health systems, particularly where private sector approaches can be leveraged for greater impact. Prior to MSD for Mothers, Tayo led the establishment of an adolescents and youth constituency at The Partnership for Maternal, Newborn and Child Health (PMNCH), a multi-constituency partnership hosted by the World Health Organization, to advocate for better sexual, reproductive, maternal, newborn, child, and adolescent health policies and services at global, regional, and national levels. Additionally, he contributed to the development of the Global Strategy for Women's, Children's, and Adolescents' Health 2016-2030. Previously, in collaboration with multi-sectoral partners in Nigeria, he contributed to the passage of the National Health Bill, the development of the National Gender Policy Guidelines and the passage of Violence Against Person's Prohibition in support of gender equality. Tayo also spearheaded Abbott's HIV patient relations function within Europe, developing services to support people living with HIV by partnering with community organizations. He advocated for anti-retroviral drug access across Africa and developed a health care professional (HCP) train-the-trainer program that has educated over 3,000 HCPs. Tayo earned a BSc in Management Sciences from Loughborough University, and a MSc in Information Technology for Management from Coventry University. Tayo is also an elite athlete in the Triple Jump with a Bronze medal at the European U23 Championships.

Meshell R Baker is a DEI certified sales confidence igniter and an accomplished, high-energy sales leader with over 20 years of proven success. She teaches business owners and sales leaders how to tap into the unlimited human potential to create diverse and inclusive culture change and disrupt the sales training status quo. After 25+ years of successful sales and leadership career and entrepreneurial expertise working with companies that include Johnson & Johnson, Thermo Fisher, Merck, Sharpe & Dohme, Dell, Microsoft, YMCA, she is on a mission to change the way Selling is perceived. She believes when sales training is delivered by incorporating confidence, diversity, equity, and inclusion as part of their core tenets, it becomes transformative for organizations, sellers, and buyers. In this episode you'll learn how to strengthen your purpose mindset, strengthen confidence, and the differences between goals, visions, purpose. Key moments: 08:30 - It didn't happen to you, it happened for you 16:00 - Building confidence in sales 28:00 - Frameworks for building an optimistic mindset 34:50 - Meshell's favorite transformation stories 41:15 - What is sales all about? Connect with Meshell https://www.linkedin.com/in/meshellrbaker/ (LinkedIN) https://meshellrbaker.com/ (Website) Connect with Us! https://www.linkedin.com/company/53108426/admin/ (LinkedIN: ) https://stories-of-selling-human.captivate.fm/ (Website: )

Welcome to Her Ambitious Career, the personal branding and success podcast for corporate women who want to land dream opportunities in their careers.  In Episode 12, ‘Principles of Authenticity for Women Leaders', my guest Kate Sibbett and I are talking about authenticity, whether you can indeed show up as your authentic self at work, whether it shows weakness or strength.  Highlights:  The 3 core principles of Authentic Leadership How women can be authentic in their leadership at work, build trust and be results-driven The benefits of Adaptable Leadership And leveraging your authentic strengths  Episode Quotes: “People are expecting more from their leaders and the next skill up is the emotional piece [being more empathetic].”  “I have learned that change is the only constant, and we must learn to adjust, adapt, and never lose the desire to progress and challenge ourselves personally and professionally.”  “We take for granted how much we [women] actually do in a day because it's expected.” (Kate Sibbett, guest on Her Ambitious Career podcast) Guest Bio:Kate Sibbett is a mum of two-year-old twin boys, she's south African and has now lived for over a decade in UK and a decade in Singapore too. Her corporate background is in Events (BCD Meetings & Events, focusing on Strategic Meetings Management for blue chip companies within the Finance and Pharmaceutical sector and Merck Sharpe and Dohme, as Regional Head of Operations for MSDs Travel, Meetings and Corporate Card Program). Kate is also one of the co-founders of She Brilliance, a mentoring program established in Singapore to help women grow in confidence and build greater purpose in their lives and careers. "I want to give back and be part of something bigger than myself," Kate says, "To live life with a purpose that, in turn, helps others.  I have always had a passion for women supporting women, and effective leadership. She Brilliance is such an exciting project!" To connect with Kate: https://www.linkedin.com/in/katesibbett  To find out more about the She Brilliance event in Singapore on 29 October 2021: www.shebriliance.org ***** Host Bio: Rebecca Allen is a Career Success Coach for ambitious women who want more from their lives and careers. She has worked over the last 10 years with clients from companies including ANZ Bank, Origin Energy, J.P. Morgan and Coca-Cola Amatil and loves getting those excited phone calls from clients saying they've been promoted, have negotiated a seismic pay rise or have moved into a role completely aligned with their mission, values and strengths.  www.illuminategrowth.com.au ****** Download your FREE gifts:'The 7 Habits of Female Execs Who Get Promoted' - get promoted faster with these tried and tested strategies.'The Perfect Pay Rise Script' - get my 9-step negotiation strategy as well as a series of scripts you can just follow!******Connect with Rebecca:> Book a free 15-minute Career Strategy Call > Connect on Linkedin> Private facebook group 'Career Success for Ambitious Women'

最近由德國藥廠 Merck Sharp & Dohme 研發的新冠口服劑 Molnupiravir 廣受世界注目。究竟這隻口服劑是一種怎麽樣的藥物？它如何發揮對抗新冠病毒的功能？

Entrevista de Carlos Mira en Mira quién Habla a Gabriela Bugarin, medica infectologa en Merck, Sharp & Dohme, porque empresa farmacéutica Merck Sharp & Dohme (MSD) anunció que su píldora experimental COVID-19 redujo a la mitad las hospitalizaciones y muertes en personas recientemente infectadas por el coronavirus.

Alex Edmans is a professor of finance at London Business School and the author of the book, "Grow the Pie: How Great Companies Deliver Both Purpose and Profit". He is an expert in corporate governance, executive compensation, corporate social responsibility, and behavioral finance. He has spoken at the World Economic Forum in Davos, at the World Bank Distinguished Speaker Series and in the UK House of Commons, and given multiple TED Talks. Alex graduated from Oxford University and then worked for Morgan Stanley in investment banking (London) and fixed income sales and trading (New York). After a PhD in Finance from MIT Sloan as a Fulbright Scholar, he joined Wharton in 2007 and was tenured in 2013 shortly before moving to LBS. Learn more about Alex at: alexedmans.com Timestamps: 0:00 - Introduction 05:51 - Laurie Hodrick's Influence on Alex 09:41 - What drives Alex as a Professor? 12:46 - Role of Technology in Dissemination of Knowledge 18:36 - About Alex's Book - Grow the Pie 21:10 - Addressing the Dilemma of Purpose vs Profits 24:23 - Short-term vs Long-term Value 29:13 - Grow the Pie Mentality for Individuals and Startups 32:25 - Using Metrics to get Feedback 37:10 - Can we rely on companies to stay committed? (Corporate Ethics) 45:18 - What does Alex's Utopia look like? Mentioned in the Podcast: 1) Laurie Simon Hodrick is a Visiting Professor of Law and Rock Center for Corporate Governance Fellow at Stanford Law School, a visiting fellow at the Hoover Institution at Stanford University, and the A. Barton Hepburn Professor Emerita of Economics in the Faculty of Business at Columbia Business School. 2) 10 Questions: www.ft.com/content/c5c386a8-64fb-11e0-9369-00144feab49a 3) Mathew Syed - Matthew Syed is an author and highly acclaimed speaker in the field of high performance. He has written six bestselling books on the subject of mindset and high performance – Rebel Ideas, Bounce, Black Box Thinking – and has worked with many leading organizations to build a mindset of continuous improvement. 4) Quantified Self Revolution - The Quantified Self is an international community of users and makers of self-tracking tools who share an interest in “self-knowledge through numbers." quantifiedself.com 5) Merck & Co., Inc - d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. 6) Unilever - Unilever is an Anglo-Dutch multinational consumer goods company headquartered in London, England, and Rotterdam, Netherlands. 7) Paul Polman - Paulus Polman is a Dutch businessman. He is a former Procter & Gamble president for Western Europe. In 2006 Polman joined Nestlé as chief financial officer and became vice president for the Americas in February 2008 8) Alan Jope - Alan Jope is a Scottish businessman, and the CEO of Unilever since January 2019, succeeding Paul Polman. 9) Roy Vagelos - Pindaros Roy Vagelos, better known as P. Roy Vagelos or Roy Vagelos, is an American physician and business executive, who was president and chief executive officer and chairman of the American pharmaceutical company Merck & Co. Since 1995, Vagelos has served as chairman of the board of Regeneron Pharmaceuticals. --- Send in a voice message: https://anchor.fm/utopia-is-now/message

Sources for this episode include: https://www.cbsnews.com/news/48-hours-live-to-tell-one-last-hug/https://www.abcactionnews.com/news/region-south-pinellas/st-petersburg/man-arrested-in-26-year-old-sexual-assault-cold-case-connected-to-another-high-profile-crimehttps://www.bbc.com/news/magazine-38302839https://www.baynews9.com/fl/tampa/news/2018/05/04/deputies-arrest-man-sexual-battery-cold-casehttps://www.crisiscenter.org/pdfs/generational_effects_of_violence_doc.pdf--- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/appSupport this podcast: https://anchor.fm/stephanie-garcia180/support

Todos tenemos un pasado y, evidentemente, los científicos también. Parte de lo que son los sanitarios e investigadores depende de la formación que han recibido, por lo que para entender realmente la situación científica de un país hace falta analizar a fondo cómo forma a sus pupilos.Para tratar este tema tenemos con nosotros a Anabel Learte, que es Doctora biología por la Universidad de Birmingham. Tras pasar un período de formación en el departamento de Química Física en la Universidad de Salamanca, y en la empresa farmacéutica Merck, Sharp and Dohme, se dedicó a la investigación estudiando el desarrollo del sistema nervioso en la mosca de la fruta Drosophila melanogaster. Durante los últimos años, como docente de diferentes asignaturas de ciencia básica en grados de Ciencias de la Salud ha desarrollado un interés especial por conocer mejor las metodologías docentes que pueden facilitar una integración de las asignaturas básicas con las más clínicas y ha desarrollado estrategias como la metodología WSLA para llevarlo a cabo. Actualmente su interés en el campo de la educación médica se centra en el papel de las redes sociales como apoyo y recurso docente, y coordina el proyecto de divulgación científica FECyT Ciencia y Vida Scicomm, donde se busca divulgar ciencia relacionada con la salud y las humanidades

Although breast cancer was once considered a “non-immunogenic” cancer, numerous studies demonstrate PD-L1 expression in the breast cancer micro-environment, and now several immune checkpoint inhibitors are under investigation in this patient group. To help us to interpret the results of all of these trials and to begin thinking about how this class of drugs fits into breast cancer treatment plans, we've invited Professor Peter Schmid, Centre Lead of the Centre of Experimental Cancer Medicines at Bart's Cancer Institute, London, to answer our questions on the topic. References: Plaines-Laine, et al. Cancers (Basel). 2019; 11(7): 1033 Cyprian, et al. Bosn J Basic Med Sci. 2019; 19(3): 227-233 Schmid, et al. N Engl J Med. 2020 Feb 27;382(9):810-821 Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn. This episode is supported by an educational grant from Merck, Sharpe and Dohme corp., who has had no influence on the content or choice of faculty.

Two women survive separate ordeals, one domestic abuse and the other a hostage situation. Support the show (https://www.patreon.com/user?u=25398556)

SoroScouts- Ep.17 - Condecorações e Reconhecimento Prêmio Walter Dohme com Chefe Gú e Morgana

Merck's History of Crimes and Misdemeanors   Richard Gale and Gary Null Progressive Radio Network, June 1, 2020 Which private corporation has likely been responsible for the deaths of more innocent people than any terrorist organization or military regime change in Afghanistan, Iraq, Libya, Syria and elsewhere?  For us, the answer is evident:  Merck and Company. Iatraogenic medicine, or medical error, is now the third leading cause of death in the US after cardiovascular disease and cancer. The majority of these deaths are caused by FDA approved drugs' adverse effects and from patients taking multiple medications without thorough clinical research to determine the safety of their synergistic effects.  Consequently our health agencies' oversight and monitoring of drugs on the market is dismal.    One of the worst corporate deals the US government may have ever made in modern history was to acquire the American subsidiary of the German pharmaceutical firm Merck and Company during the first world war. Later in 1953, Merck acquired a competitive drug maker Sharp and Dohme, thereby establishing itself as America's largest drug developer and manufacturer. Since then this corporate Medusa has ensnared thirteen other drug firms, including Scherring Plough, which it acquired for $41 billion. The two pharmaceutical giants had earned $47 billion in combined sales at the time the merger was finalized in 2009.   Merck's life of criminal behavior was observed back in the 1970s. In 1975, it was busted by the SEC for illegal payments to foreign government officials from "approximately" 36 nations. The scam was orchestrated through personal bank accounts with the sole purpose of advancing drug approvals through foreign nations' regulatory medical agencies.     One of the largest frauds in recent medical history was the company's anti-inflammatory drug Vioxx that resulted in fines above $4.8 billion for causing over a minimum 60,000 deaths from sudden heart attacks and over 120,000 serious medical injuries. At its height, Vioxx was earning over $2 billion in revenues annually and it is estimated that 25 million patients were prescribed the medication. The securities class action suit against the company alone reached $1 billion, placing it in the top 15 securities lawsuits in US corporate history. The centerpiece of the crime was Merck's intentional withholding of scientific data about the drug's adverse cardiovascular side effects.    Years after the settlement, Ron Unz, the publisher of The American Conservative, undertook his own investigation to validate Vioxx's death toll. Analyzing the drug's adverse effects over a longer time period, Unz estimated Merck may have been responsible for nearly half a million premature deaths in elderly patients, the drug's primary target group. That is roughly the same number of total civilian, military and terrorist deaths from the US's military escapades in Afghanistan, Iraq and Pakistan combined.    Merck's settlement of 47,000 pending lawsuits for personal injuries and 265 class action cases was a small pittance for the harm Vioxx left in its wake. Merck executives were never properly punished for willingly concealing the drug's dangers in order to assure FDA approval.    In Australia, Merck's efforts to increase Vioxx profits employed other forms of malfeasance. The Australian government launched a class action suit against the drug maker on charges that employees schemed a fake scientific paper that was ghostwritten for a medical journal in order to put Vioxx into a positive light. Testimonies during the trial stated data was completely based upon "wishful thinking." Merck also founded the peer-reviewed journal Australasian Journal of Bone and Joint Medicine. The journal was a fraud; it was not properly peer-reviewed and its primary purpose was to promote Vioxx on the Australian continent.    Moreover, the class action lawsuit contained Merck emails accessed by Australian officials. The company's internal communications ordered select employees to draft up a hit list of physicians who were critical of Vioxx. According to the documents, these physicians were targeted to be "neutralized" or "discredited." Some, including Dr. James Fries at Sanford University's medical school, were clinical investigators who happened to speak out about the drug's shortcomings. One email said, "We may need to seek them out and destroy them where they live..."     Efforts to target critics for harassment is not limited to Merck. Earlier, Monsanto earned a similar reputation. The Monsanto's parent company Bayer had to release a public apology for the discovery of a Monsanto hit list of 200 French journalists and politicians who opposed glyphosate and its GMO crops. It has acted similarly in other countries including the US, according to veteran journalist Carey Gillam.  The list originated from the multinational public relations firm Fleishman Hillard. Merck has also employed Fleishman Hillard as well as Monsanto's other notorious PR firm Ketchum. One of Merck's Executive Directors, Ian McConnell, earlier served as a vice president at Fleishman. The PR firm's senior adviser on healthcare Dr. Lukas Pfister, was at Merck for 25 years in its government affairs unit. Merck's revolving door is not limited to our federal health agencies, but also fully infiltrates some of the world's most shadowy international PR firms that specialize in whitewashing the public images of executive elites, corporations and in the case of the PR firm Burson-Marsteller even dictators. Following the Vioxx case, Merck had hired B-Marsteller to clean up its public image. MSNBC reported back in 2009, "When evil needs public relations, evil has Burson-Marsteller on speed dial."   But Merck's efforts to conceal the dangers of its products, falsify data about drugs' efficacy and safety and exaggeration of medical claims go back sixty years. In the 1960s, the FDA discovered that the drug maker's arthritis medication Indocin had not been properly tested for efficacy and its adverse effects were being completely ignored.  In the 1970s, Merck's drug dietheylstilbestrol (DES) prescribed for the prevention of miscarriages caused a flurry of vaginal cancer cases and other gynecological disorders. Merck had all along known that DES was carcinogenic based upon its own animal clinical trials. In 2007, its cholesterol drug Zetia was shown to increase liver disease. Again Merck had known about Zetia's liver risks but withheld the clinical trial's damning results.    It would also appear that Merck has managed to hijack US courts as well. This includes an early 2019 ruling by Trump's corporate-friendly US Supreme Court to side with the drug maker and squash hundreds of lawsuits for failing to issue warnings that its osteoporosis drug Fosamax's may contribute to debilitating bone breaks. A federal court in California found that Merck committed perjury for lying in a patent infringement case against Gilead Sciences over the latter's blockbuster Hepatitis C drug Sovaldi. The judge ruled that Merck carried out a "systematic and outrageous deception in conjunction with unethical business practices and litigation misconduct."  It turned out that Merck's patent claims were a sham and orchestrated by its legal division.   Besides pushing through the FDA dangerous medications onto the market, the company has also found itself in the courtroom on many occasions for price-fixing, routinely defrauding and overbilling states' Medicare and Medicaid programs, and violating the Anti-Kickback Statute. In 2006, the IRS went after Merck for owing almost $2 billion in back taxes. According to the Wall Street Journal, Merck partnered with a British bank to create an offshore subsidiary in tax-friendly Bermuda to divert taxable revenue on its bestselling cholesterol drugs Zocor and Mevacor through a patent scheme. The company ran the operation for ten years before the FDA uncovered the racket.    Merck is America's leading vaccine manufacturer. Despite public perception and the ruse that vaccines are somehow safer and more effective than pharmaceutical drugs in general, it is the same industry and corporate culture that manufactures both them. Currently Merck markets vaccines for Haemophilus B, Hepatitis A and Hepatitis B (individually and in combination), human papilomavirus (Gardasil), Measles, Mumps and Rubella (MMR), pneumococcal, rotavirus, varicella (chickenpox) and Zoster virus (for shingles). More recently it has jumped into the coronavirus vaccine race. In 2010, Merck obtained exclusive rights to MassBiologics vaccine portfolio. The consequence is that Merck's Adult Vaccine Portfolio expanded to include 9 of the 10 vaccines on the CDC's adult immunization schedule. The company now holds almost a full monopoly on the government's vaccines    On its website, the FDA assures the public that "Vaccines, as with all products regulated by the FDA, undergo a rigorous review of laboratory and clinical data to ensure the safety, efficacy, purity and potency of these products."  However, except for Gardasil, not a single one of Merck's vaccines has ever been tested in a scientifically viable double-blinded placebo controlled trial. In each case, the placebo in the control group was not inert, such as the use of sterile saline. Rather Merck only tested the vaccine with the viral component against a faux placebo containing the same ingredients, including aluminum, but minus the virus. Known as a "carrier solution," the standard scientific protocol does not designate it as a proper placebo for measuring the efficacy and disease risks of a drug. And in the case of Gardasil, the trial was statistical trickery to mask Gardasil's adverse effects. Therefore the FDA's claim is patently false. None of Merck's vaccines have ever undergone a "rigorous review" prior to regulatory approval.    Although not completely innocent from internal unfairness and conflicts of interest, the Cochrane Database Collaboration arguably remains the most reliable resource for analysis of drugs, vaccines and medical devices in the evidence-based medical establishment. In its 2016 analysis of Merck's human papillomavirus vaccine Gardasil, the investigators were so alarmed they filed a complaint against the European Medical Agency for failing to adequately assess the vaccine's neurological harms.    As we have recently witnessed with Monsanto's Roundup and Bayer's settlement of $10 billion to cover 80,000 lawsuits, Gardasil may very well become the company's Achilles heel. The Gardasil scandal may very well begin to topple the vaccine regime and raise the public's already increasing awareness and distrust in the official mantra that vaccines are safe and effective. The development, scientific rationale, fraudulent clinical trials and data reporting, and inside negotiations with federal health officials to market the vaccine to pre-teen and teen girls and boys, is a story riddled with misconduct. Today it is Merck's third largest revenue-generating drug after its cancer drug Keytruda and diabetes drug Januvia, earning $3.1 billion in 2018. Its MMR vaccine is fifth having earned $1.8 billion. Gardasil's success has nothing to do with the prevention of an urgent national health need. Instead it was a business strategy through Merck's influence over our nation's regulatory agencies and state politicians whose election campaigns it funds.    In 2018, a French oncologist, Dr. Gerard Delepine, stumbled upon a correlation between the increase of cervical cancer rates with the rising rates of Gardasil vaccinations. Delepine also compared France, which was deliberating on whether to mandate HPV vaccination, with other countries that relied upon pap smears as a preventative measure against cervical cancer. He observed that in all countries that prioritized pap smears, cervical cancer rates were decreasing; whereas, in those countries with higher HPV vaccination compliance, the rates increased. In his letter to the French government in defiance of Merck's lobbying efforts, Delephine stated:   "A compulsory health measure should not be based on faith in vaccination or hidden conflicts of interest, but on proven facts, verifiable by every citizen. However, the facts established by the official records of cancer registries show that HPV vaccination does not protect against invasive cancer of the cervix, but seems rather to maintain its frequency at a high level and sometimes even increase it."   An article published in the French journal Agoravox noted that other national health ministries are coming around to acknowledge that Gardasil is an extremely unsafe vaccine. Japan, Austria and Denmark no longer promote it due to is trail of injuries with fatal consequences. Public demonstrations against Merck's Gardasil have occurred in Japan, Colombia, and Ireland.    Yet none of these efforts to warn the public about Gardasil's risks have reached the American media. Hopefully this may change. Medical researchers at the University of South Alabama presented their paper at the Society of Gynecologic Oncology's annual conference. There is great disparity between HPV vaccine compliance across Alabama counties, which range anywhere between 33 and 66 percent. Yet the epidemiological data suggests there is no evidence that Gardasil lowered cancer rates in counties with higher vaccine uptake. Moreover, there is zero chance of pre-teens and teens getting cervical cancer. The average age for the onset of the cancer is 50 years. Nor has the vaccine been on the market long enough to determine whether it protects a woman when she reaches even close to that age. Its product insert for physicians states the vaccine "may not result in protection in all vaccine recipients" and it "has not been demonstrated to prevent HPV-related CIN 2/3 [abnormal pre-cancerous cervical cells] or worse in women older than 26 years of age." Consequently, there is no scientific rationale for states to mandate the HPV vaccine for schoolchildren let alone even vaccinating them in the first place. In addition, the federal agencies and Merck market the vaccine under a false pretext that HPV infection is the leading cause of cervical cancer; correctly, only a third of cervical cancer cases are caused by the virus.    Robert Kennedy Jr is currently taking steps to sue Merck over the Gardasil deception. Merck's first effort to have the class action suit dismissed was overturned by the court. Kennedy's in-depth investigations through his Children's Health Defense organization has uncovered evidence that the vaccine increases birth defects in children conceived of HPV-vaccinated moms; miscarriages have increased 2000 percent above normal, and girls are experiencing serious reproductive complications, including infertility, at approximately ten-fold above the normal rate. During an interview on the Progressive Radio Network, he noted that there was 10 times greater risk of dying from cervical cancer among Gardasil trial participants compared to the general public. There is a 10-fold increase for ovarian failure, and 1 in 37 girls who receive the vaccine will experience an autoimmune disease after 6 months of receiving the series of injections. When we consider that 1 in 37,000 women have a chance of dying from cervical cancer, it puts HPV vaccines into a completely different light. Sadly, across the nation, politicians from both sides of the aisle in state legislatures, notably Governor Andrew Cuomo in New York, are doing Merck's bidding to mandate Gardasil for all girls and boys upon entering school.    Based upon Kennedy's research and documents received from Freedom of Information Act filings, during Merck's own Gardasil clinical trials, 2.3 percent of girls and women between the ages of 9 through 26 developed a serious autoimmune disease and crippling neurological disorders within seven months of vaccination. Among the 10,700 who received the actual vaccine, 245 (2.3%) had an autoimmune disorder; among the 9,412 who received either an "AAHS Control" -- the aluminum hydrophosphate sulfate adjuvant solution with other ingredients minus the HPV virus vectors, there were 218 (2.3%) life-threatening injuries. The most frequent adverse effects were arthritis and anthropathy, autoimmune thyroiditis, celiac disease, hyperthyroidism and hypothyroidism, inflammatory bowel disease, psoriasis, Raynaud's Phenomenon, rheumatoid arthritis and uveitis. In other words, it was the aluminum adjuvant responsible for this enormous suffering. He stated during the Progressive Radio Network broadcast that according to Merck's own statistics, girls are one hundred times more likely to experience a serious adverse effect from the vaccine than to be protected from cervical cancer.    In a 2012 article published in the Journal of Law and Medical Ethics, researchers at the University of British Columbia wrote that ever since Gardasil was approved in 2006, Merck has engaged in an "overly aggressive marketing strategies and lobbying campaigns aimed at promoting Gardasil as a mandatory vaccine."  One strategy Merck has employed is to take advantage of FDA loopholes to fast track its drugs. In the case of its expanded Gardasil-9 for adults between the ages of 27 to 45, the company applied for fast tracking two days after the Journal of Toxicological and Environmental Health published a study that the HPV vaccine was lowering the probability of pregnancy for women in their 20s.   Unfortunately, the media has indiscriminately colluded with Merck's scam. Drug companies, according to Kennedy, pay $4.5 billion to the major media networks and publications to promote their drugs. And none of the media outlets are willing to sacrifice their profits for advertising drugs on moral and ethical grounds.    Another scandal erupted within Merck's vaccine business in 2010 after two whistleblowers gave testimony that the mumps' component in its Measles-Mumps-Rubella (MMR) vaccine was based on fraudulent data about it's efficacy, and the company knowingly proceeded in order to corner the mumps vaccine market. Merck had been defrauding the US government, which purchases the MMR, for a decade. The government and the two Merck whistleblowers, virologists Stephen Krahling and Joan Wlochowski, filed a lawsuit against Merck for being in violation of the False Claims Act. According to the charges, Merck had "falsified its mumps vaccine test results to hit an efficacy rate of 95 percent. The company achieved this by adding "animal antibodies to a blood sample to give the impression of increased antibodies." This would certainly explain why mumps outbreaks in summer camps and on college campuses are found to occur among those vaccinated.    Merck's has gained enormous political and social influence over the national perception about vaccines.  One example is Merck's behind the scenes aggression against the flim Vaxxed.  When the documentary film was officially selected to screen during the 2016 Tribeca Film Festival in Manhattan, we discovered in an earlier report that Merck left its fingerprints on the film's removal and censorship. The Alfred Sloan Foundation is the festival's largest sponsor; pro-vaccine advocate Bill Gates is also a notable contributor. One of the leading persons on the Foundation's board of trustees was Dr. Peter Kim.  Kim happens to be the former president of Merck's Research Laboratories who was directly responsible for the launch of Gardasil and Merck's other vaccines for the Zoster virus and rotavirus. The film presents a harsh indictment against Dr Julie Gerberding, the former head of the CDC who coordinated the cover up of data that confirmed thimerosal's role in the onset of autism. After managing the agency's operations to mine sweep the data and generate new manipulated studies with public funds to suggest thimerosal's safety, Gerberding accepted her reward from the pharmaceutical industry by becoming the head of Merck's vaccine division. In addition, according to the whistleblowing of a senior CDC scientist, Dr. William Thompson, Gerberding was responsible for destroying the CDC's research that showed African American boys were at a substantially higher risk of becoming autistic from Merck's MMR vaccine. Fortunately, Dr. Thompson, who was present during the order to shred documents, saved copies which he subsequently turned over to Congressman Bill Posy and an independent biologist Prof. Brian Hooker. Since then, Congress has failed to hold hearings.    All told, these examples of Merck's culture of greed, deception, political maneuvering and illegal aggression has collectively injured countless people. Merck is a global corporation. Its products, like Monsanto's glyphoste, are marketed globally. To better understand Merck, the company should be perceived foremost as a cash cow for Wall Street. Its prime directive is selling drugs; its history of misdemeanors and criminal activities should indicate the company holds little integrity in its commitment to prevent and treat disease. The full extent of the casualties from Merck's drugs and vaccines may never be properly calculated. For firms such as Merck and Monsanto, injuries and deaths are the necessary collateral damage of getting poorly tested products on the market and as fast as possible. A black box should be slapped on the Merck logo.    What is important at this moment is that many corporations are fast-tracking, without sufficient long-term animal and human clinical trials, Merck is now aggressively making efforts to beat out its competition with a Covid-19 vaccine.  Do we really want to trust such a company with this reputation with a Covid vaccine? Therefore we recommend people to support the efforts of Bobby Kennedy and the Children's Health Defense in its lawsuit against Merck's Gardasil. A victory may well weaken the entire edifice of vaccine pseudoscience and the public will realize that for decades it has been little more than a house of cards.

Combining her fascination with movie stars and communist dictatorships, Lauren tells the wild tale of two South Koreans kidnapped and put to work by Kim Jong-il in the 70s. Then Megan... well, Megan does what she does best – shares a topic that is devastating and makes Lauren yell a lot. Enjoy, freaks! 

Merck Sharp & Dohme Corp. v. Albrecht | 01/07/19 | Docket #: 17-290

Merck Sharp & Dohme Corp. v. Albrecht

Daniel Dohme ist heute unser Gast in der Franchise-Rockstars Podcast-Folge. Daniel ist Franchisenehmer bei zwei verschiedenen Systemen. Als erstes machte er sich mit dem System ISOTEC selbständig, dann folgte German Homes. Zusätzlich hat er aber noch die Clay Court Holding GmbH gegründet. Was diese genau macht, erzählt er uns in dieser Ausgabe. Webseiten: Clay Court Holding GmbH ISOTEC German Homes Kontakt: dohme@isotec-hannover.de t.dohme@germanhomes.de